Pharma ADMET testing refers to a group of laboratory and computational processes used in the pharmaceutical industry to evaluate the absorption, distribution, metabolism, excretion and toxicity (ADMET) profiles of drug candidates. It is an essential component of the drug discovery and development process, allowing researchers and developers to assess how a new compound behaves in the body and its potential safety risks before proceeding to clinical trials.
The pharma ADMET testing market consists of sales, by entities (organizations, sole traders, or partnerships) is used by pharmaceutical companies, biotechnology firms, contract research organizations (CROs) and academic research institutions. The testing is conducted at early and preclinical stages of drug development and continues through the early phases of clinical trials to eliminate compounds with unfavorable pharmacokinetic or toxicity profiles.
The global pharma ADMET testing market was valued at $6,062.9 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 11.0%.
Rising Pharma-Related R&D Spending
During the historic period, the pharma ADMET testing market was driven by rising pharma-related R&D spending. Increasing funding toward drug discovery and development resulted in a greater number of compounds entering early-stage screening, thereby intensifying the need for comprehensive ADME and toxicology evaluation. This rise in investment supported deeper scientific exploration, accelerated development cycles and encouraged pharmaceutical companies to expand their research portfolios. For instance, in December 2024, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), a global industry body representing research-based biopharmaceutical companies, published its Always Innovating: Facts & Figures report, highlighting that the top 50 pharmaceutical companies invested USD 167 billion in R&D in 2022, marking a 60% increase compared with 2012. The report emphasized the sector's commitment to scientific advancement, strengthened innovation capacity and expansion of research pipelines across the world. Therefore, the pharma ADMET testing market was driven by rising pharma-related R&D spending.
Establishment Of Dedicated Peptide Laboratories To Support Pharma ADMET Testing
Major companies in the pharma ADMET testing market are focusing on the establishment of dedicated peptide laboratories designed to support the growing demand for peptide-based therapeutics and streamline ADMET and preclinical workflows. These developments emphasize enhanced peptide synthesis capacity, automation-driven throughput, and integrated purification and quality-control processes to meet rising requirements for high-quality, scalable testing inputs. For instance, in October 2025, Syngene International, an India-based contract research, development and manufacturing organization, launched a state-of-the-art peptide laboratory and advanced automation systems in its DMPK and Direct-to-Biology operations, aimed at improving efficiency, consistency, and scalability for ADMET testing and drug-discovery support. By leveraging modern automation technologies and specialized peptide infrastructure, the company aims to deliver a more efficient, reliable and scalable solution, enabling faster, more robust ADMET testing services to meet evolving needs in both domestic and global pharmaceutical markets.
The global pharma ADMET testing market is fairly fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 11.92% of the total market in 2024.
Pharma ADMET Testing Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global pharma ADMET testing market as it emerges from the COVID-19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for pharma ADMET testing? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The pharma ADMET testing market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider pharma ADMET testing market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by testing type, by technology, and by application.
- Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis And Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Global Market Size And Growth Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by testing type, by technology, and by application in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
- Competitive Dashboard- Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Recent Developments Information on recent developments in the market covered in the report.
- Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations- This section includes recommendations for Pharma ADMET testing providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
- 1) By Testing Type: In Vivo ADMET Testing; In Vitro ADMET Testing; In Silico ADMET Testing
- 2) By Technology: Cell Culture; High Throughput; Molecular Imaging; OMICS Technology
- 3) By Application: Systemic Toxicity; Renal Toxicity; Hepatotoxicity; Neurotoxicity; Other Applications
- Companies Mentioned: Thermo Fisher Scientific Inc. (PPD ICON plc); IQVIA Inc.; Charles River Laboratories International Inc.; Laboratory Corporation of America Holdings (Covance Inc.); Eurofins Scientific SE
- Countries: China; India; USA; South Korea; Japan; Brazil; Indonesia; Germany; UK; Russia; France; Italy; Canada; Spain; Australia
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time-series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; pharma ADMET testing indicators comparison.
- Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.